Dr. Clarence L. Young has nearly 25 years of drug development and research experience from the pharmaceutical industry as well as academia. Over the course of his career he has provided medical oversight of numerous clinical trials, regulatory filings, and product launches.

Prior to joining Iroko, he was Vice President Targeted Therapies and Integrated Hospital Care at Novartis Pharmaceuticals Corporation, responsible for leading cross-functional teams in development, global registration and commercialization of small and large molecules.

Dr. Young previously held senior research positions at SmithKline Beecham, GlaxoSmithKline and Protez Pharmaceuticals (a wholly owned subsidiary of Novartis Pharmaceutical Corporation), leading clinical efforts across therapeutic specialties.

He has served on key industry boards and has authored numerous scientific papers published in primary, peer-reviewed journals. He has also received many awards and honors from the industry, non-profit organizations and governmental agencies over the course of his career. 

Dr. Young is Board Certified in Internal Medicine. He is a graduate of Harvard Medical School.